Member Info for Sisu

Chris Abell: "Many of the potential partners we are talking to are awaiting some of those data in order to make decisions."

Christina Coughlin: "We do have substantive conversations with a number of partners under NDA across different assets. These discussions are constructive. They are progressing."

Super excited about a transformational 2H - just put yourselves in the shoes of BP in these talks, AVCT hold all the cards and they know it.

"discussions with multiple parties on potential partnering of first, second and third generation assets"

Left Ventricular Ejection Fraction (LVEF) measures the percentage of blood pumped out of the heart's main chamber with each beat.

Standard Doxorubicin: is a chemotherapy drug that can cause a dose-dependent, progressive decline in left ventricular ejection fraction (LVEF)

AVA6000: "Exposure-response analysis found that there was not a meaningful relationship between LVEF changes and released doxorubicin exposure"

Huge.

With previous data already showing tumour shrinkage/regression in 9 out of 30 salivary gland cancer patients (!) and disease control in around 90% overall, I'm excited about tonights data release.

If the updated data continues to show prolonged progression-free survival alongside minimal cardiac toxicity (despite patients receiving exposure levels that would normally severely limit conventional Doxorubicin use), it all points to Avacta expanding the therapeutic window of one of oncology’s most powerful chemotherapies.

Let's hope for current patients, and millions of potential future patients (as well as the company and investors) - for data showing patients remaining progression-free for far longer than historical naked dox expectations, while continuing to tolerate cumulative dox exposure levels that would normally cause severe cardiac toxicity. There's not a chance that gets overlooked by some big names.

Avacta CEO: “..the only technology that is capable of delivering cancer treatment drugs directly to the tumor at the precise concentrations our payloads can achieve - and without triggering severe toxic side effects.”

There has been some really subtle but gargantuan adaptations in communication in recent week. Fantastic

I'd strongly recommend jumping to 17m44 in Part II of the Science Day Video. Now, listen carefully to all Alex Spira says, who is a lead investigator on the trial.

18m33: "Here you basically have a drug thats activated only at the tumour site, because the drug is activated only when its at the tumours.... and that's super important for lots of reasons"

"Here you basically have a drug - that's activated only at the tumour site".

How do most cancer therapies fail? The more you hit the tumour, the more you damage the patient. So the utopian scenario, is this level of precision. This is the CSO of NEXT Oncology, saying very clearly that this mechanism may solve one of the most central issues in oncology.

A quick breakdown of direct quotes around this section (Spira & Dave Liebowitz):

- "Activated only at the tumour site" which implies a cleaner therapeutic index, (i.e. potentially much less systemic exposure/toxicity)

- "We deliver a lot more of that because of the safety" - because of the localised activation, you can safely administer higher payload

- "We get really sustained inhibition of tumour growth long after the last dose" - hows that for durable anti-tumour activity and prolonged tumour exposure?

- "You can see that we get really very deep responses with AVA6103" - this is a major implication, think large tumour shrinkage

Makes sense why CC is grinning from ear to ear for the majority of the videos.

I'd strongly recommend jumping to 17m44 in Part II of the Science Day Video. Now, listen carefully to all Alex Spira says, who is a lead investigator on the trial.

18m33: "Here you basically have a drug thats activated only at the tumour site, because the drug is activated only when its at the tumours.... and that's super important for lots of reasons"

"Here you basically have a drug - that's activated only at the tumour site".

How do most cancer therapies fail? The more you hit the tumour, the more you damage the patient. So the utopian scenario, is this level of precision. This is the CSO of NEXT Oncology, saying very clearly that this mechanism may solve one of the most central issues in oncology.

A quick breakdown of direct quotes around this section (Spira & Dave Liebowitz):

- "Activated only at the tumour site" which implies a cleaner therapeutic index, (i.e. potentially much less systemic exposure/toxicity)

- "We deliver a lot more of that because of the safety" - because of the localised activation, you can safely administer higher payload

- "We get really sustained inhibition of tumour growth long after the last dose" - hows that for durable anti-tumour activity and prolonged tumour exposure?

- "You can see that we get really very deep responses with AVA6103" - this is a major implication, think large tumour shrinkage

Makes sense why CC is grinning from ear to ear for the majority of the videos.

On Channel 4 (https://www.channel4.com/programmes/can-we-cure-kids-cancer/on-demand/70101-001), really really tough watch at times (understatement). Please be prepared for a deeply saddening watch.

This is real hint at the sort of technology Avacta may be on the cusp of revolutionising on a grand scale. Immunotherapies shown. Also shows Doxorubicin in action and its harrowing side effects, how effective this chemo can be but how dangerous the side effects are too.

I would whip my (somewhat) considerable investment out for a value of nothing in an instant if it meant Avacta were to be successful, to any degree, with what they are hoping to achieve.

Was just going off the Actual Study Start Date rather than date of first dosage.

Actual Study Start Date : July 16, 2021
"The actual date on which the first participant was enrolled in a clinical study."
https://clinicaltrials.gov/ct2/show/NCT04969835

Mr Andy Hayes (Sarcoma surgeon) re. Sarcoma - "There are more than 50 types, which can make it extremely difficult to find treatments that are effective."

The AVA6000 trial criteria states: "The tumour types to be explored in Phase 1b, will be determined based on evaluation of the Phase 1a data and the protocol will be amended accordingly."

AS has already iterated Sarcoma & Ovarian will be the two tumour types in P2.

Avacta chose a type of cancer to carry out their pre-clinical trials on with. This was a xenografted human sarcoma. We are now over a year(!) into the trial and the same cancer type has been specifically chosen, on assessment of full data, to progress with. I don't believe this to be coincidental.

This cancer type is extremely difficult to effectively treat, and Avacta are currently treating it (and other cancers) at a dose equiv. of 108mg of Dox - the recommended dose is 60-70mg and even at this level the side-effects are harrowing, let alone at one >150% of this.

For those that struggle to decipher the impact of this - not being able to find a MTD (maximum tolerated dose) as Avacta are not only saying, but currently showing, in the DE phase is gargantuan in what it shows. Traditional Dox has an MTD because of the severity of the side-effects seen.

Have a good day all.

5,500 sq ft upgraded to 8,800 sq ft (8 modules of 1,100 ea.)

https://www.scalespace.co.uk/news/scale-space-launches-16900-sq-ft-of-lab-space-in-white-city-innovation-district-and-signs-five-new-life-sciences-tenants

Just one of those things that once you witness it you won't forget the term. Wouldn't go out your way for one, bit nicer in a cold clean glass!

Have a good weekend all.

We're all down the Wetherby Whaler for an all day pish up. Plenty of fun and games, pin the Affimer on the test strip starting shortly. How many shumpers can one person wear was a blast. Big Al just done a shoey, it's getting lively.. :- )

Took me a few minutes there to stop laughing at 'tell tell sign'. Thanks for your post by the way, really brought a lot to the table.

I will keep this swift. Soft reminder to all, RH's & MK's family investments total well in excess of 12m shares of Avacta AFAIK. That's me only touching on openly reported ownerships. All within AIM regulations before any hawks swoop in. Aside from that - they have already totalled a multi-6 figure sum expenditure on Med19 itself. Not to touch on Saturn Pass et all.

They aren't here to sell to you and I to claw back what they have laid out only. Widen the horizon of thought and you will see their aim and perhaps, just maybe, you will see it unfold, too.

Rome wasn't built in a day and nor was this solid based BioTech. Have a good week, or two... all.

139 days since first in-human dosing of AVA6000. Almost 5 months. The data-set (they are aiming for as heavily data filled trials for full clarity) is building. FDA has granted IND application based on assessing the majority of this data.

AVA6000 is the first piece of weaponry in a large warchest.

Avacta have created the most efficcient LFT on the market. It is also, funnily enough, data-rich with performance amongst a varied CT value spectrum. It has shown its hand that other companies can't beat on performance. It does not rely on traditional monoclonal antibodies like other tests, of which are in supreme demand.

Just because we currently have no visibility of marketing, sales, manufacturing it does not mean it is not happening.
Contracts will, in my opinion, have been signed for the sale of MeduFlow. They sell every little test they make.

Happy new year Abaktarians.

Email sent. Reading it back still has me astonished at what is going on. Luckily UK is just 0.8% of the world population, eh?

Everything OK at home Nicolas?

Having two shorts in place is perversely great news when one needs the liquidity and/or cuts their losses and bails. Like a coiled spring with the added bonus of traders & holders alike jumping on the back of it too further the momentum of the rise.

May be small positions for them both respectively but I sense it may be a costly one for at least one of the two companies. Part of me hopes they stay in their positions throughout the AVA journey(s). How embarrassing & essentially immoral would that be viewed on top of monumental cash losses if/when the entire chemotherapy world has been revolutionised in so many respects.

Have a good Friday all, I think we will....

AMEDA - Sensitivity: 97.3% (95% CI: 90.0% - 99.8%).

Specimen
Nasal swab, Nasopharyngeal swab

Not sure that's quite true, AgentB.